Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Neuropharmacol ; 34(4): 139-40, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21768800

RESUMEN

The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present report, we describe an adult male patient with clomipramine treatment-resistant OCD who did not respond to augmentation with risperidone and aripiprazole but who showed clinical improvement with agomelatine. The effect of agomelatine in resynchronizing circadian rhythms may demonstrate the importance of the circadian rhythm disruption observed in OCD. Moreover, the regulation of the serotoninergic system is circadian in nature, and the resynchronization of the serotoninergic system may regulate serotoninergic dysfunction, a major factor in OCD.


Asunto(s)
Acetamidas/uso terapéutico , Trastornos Cronobiológicos/prevención & control , Trastorno Obsesivo Compulsivo/tratamiento farmacológico , Trastorno Obsesivo Compulsivo/fisiopatología , Receptores de Melatonina/agonistas , Adolescente , Trastornos Cronobiológicos/etiología , Resistencia a Medicamentos , Humanos , Masculino , Receptor de Serotonina 5-HT2C/química , Antagonistas del Receptor de Serotonina 5-HT2/uso terapéutico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA